• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Partnerships

Our partners

Home > Partnerships

Our partners

  • Our partners
  • Partnering with us

Collaboration is an essential part of DNDi’s virtual R&D model: we cannot carry out our work without the engagement of public and private partners.

Today, DNDi has forged a diverse range of alliances and research collaborations with over 200 partners and service providers in nearly 50 countries.

Industry partners and service providers
Universities and research centres
Non-profit organizations, NGOs, and networks
Healthcare providers
Ministries of health and governments

Industry partners and service providers

Loading…
AbbVie

USA

Loading…
Aminopyrazoles /
Chagas C205 series /
Chagas Hit-to-lead /
DNDI-6174 /
DNDI-6899 (GSK899/DDD853651) /
Flubendazole Macrofilaricide /
Flubentylosin /
Leishmaniasis L205 series /
NTD Drug Discovery Booster Hit-to-lead /
Open Synthesis Network /
Loading…
Pandemic Preparedness /
Hepatitis C /
test image
Accelera

Italy

Loading…
VL-2098 /
Loading…
test image
Advinus Therapeutics Ltd

India

Loading…
VL-2098 /
Loading…
test image
Ajinomoto Bio-Pharma Services (GeneDesign, Inc.)

Japan

Loading…
CpG-D35 (DNDI-2319) /
Loading…
test image
Albert David Limited

India

Loading…
Loading…
Visceral leishmaniasis /
test image
AMG Consultants

UK

Loading…
Guides to free computational chemistry tools for drug discovery /
Loading…
test image
Anacor Pharmaceuticals (now Pfizer Inc.)

USA

Loading…
Aminopyrazoles /
DNDI-5421 & DNDI-5610 /
Leishmaniasis hit-to-lead /
Oxachagas /
Screening Chagas disease /
Screening leishmaniasis /
SCYX-1330682 & SCYX-1608210 oxaboroles /
Successful screening collaboration leads to a new lead optimization project /
Loading…
test image
Analyticon Discovery Gmbh

Germany

Loading…
Loading…
Sleeping sickness /
test image
Aptuit

Italy

Loading…
Fexinidazole/Miltefosine Combination (VL) /
VL-2098 /
Loading…
test image
Asinex Corporation

USA

Loading…
Loading…
Sleeping sickness /
test image
Astellas Pharma Inc.

Japan

Loading…
iNTRODB – an Integrated system for searching drug-target proteins from parasitic protozoa genomes /
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
AstraZeneca

Sweden

Loading…
Chagas Hit-to-lead /
Leishmaniasis hit-to-lead /
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
AstraZeneca UK

United Kingdom

Loading…
Chagas Hit-to-lead /
NTD Drug Discovery Booster Hit-to-lead /
Loading…
test image
Atomwise, Inc.

USA

Loading…
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
BaseCon A/S

Denmark

Loading…
Fexinidazole/Miltefosine Combination (VL) /
Loading…
test image
Basilea Pharmaceutica AG

Switzerland

Loading…
Loading…
Chagas disease /
Sleeping sickness /
Visceral leishmaniasis /
test image
Bayer Healthcare AG

Germany

Loading…
Emodepside /
Nifurtimox-eflornithine combination therapy (NECT) /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
BenevolentAI

UK

Loading…
AI-guided discovery /
Pre-clinical profiling /
Loading…
test image
Bertin Pharma

France

Loading…
ASAQ /
Loading…
test image
Bio Zeq Kenya Ltd.

Kenya

Loading…
Miltefosine + Paromomycin combination (Africa) /
Loading…
test image
Bioclinica

USA

Loading…
Azoles E1224 /
Loading…
test image
BioDelivery Sciences International Inc.

USA

Loading…
Loading…
Chagas disease /
Visceral leishmaniasis /
test image
BioSquare

Republic of Korea

Loading…
Loading…
Visceral leishmaniasis /
test image
Boehringer Ingelheim

Germany

Loading…
Screening Chagas disease /
Screening Filarial disease /
Screening leishmaniasis /
Loading…
test image
Bristol-Myers Squibb

USA

Loading…
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
CAD Middle East Pharmaceutical Industries

Saudi Arabia

Loading…
Ravidasvir + sofosbuvir /
Loading…
test image
Calibr at Scripps Research

USA

Loading…
Nucleoside Booster /
Loading…
test image
Calvert Labs

USA

Loading…
Loading…
Cutaneous leishmaniasis /
test image
Cambrex (formerly Avista Pharma and SCYNEXIS Inc)

USA

Loading…
SCYX-1330682 & SCYX-1608210 oxaboroles /
Loading…
test image
Cardinal Systems

France

Loading…
Azoles E1224 /
Loading…
test image
Catalent

USA

Loading…
Loading…
Malaria /
test image
Celgene (now Bristol Myers Squibb Inc.)

USA

Loading…
Celgene Global Health visceral leishmaniasis series 1 /
Helminth Elimination Platform (HELP) /
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Screening Filarial disease /
Screening leishmaniasis /
Loading…
test image
Central Diagnostics

India

Loading…
Loading…
Visceral leishmaniasis /
test image
Certara (formerly Quantitative Solutions)

USA

Loading…
Azoles E1224 /
Loading…
test image
Charles River Laboratories (formerly WIL Research)

France

Loading…
Aminopyrazoles /
Chagas C205 series /
DNDI-5421 & DNDI-5610 /
Leishmaniasis L205 series /
SCYX-1330682 & SCYX-1608210 oxaboroles /
Loading…
test image
Chiron Corporation (now Novartis)

USA

Loading…
Loading…
Chagas disease /
Sleeping sickness /
test image
Cipla Ltd.

India

Loading…
2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC /
4-in-1 (ABC/3TC/LPV/r) /
ASMQ /
Loading…
test image
Cipla Ltd.

South Africa

Loading…
4-in-1 (ABC/3TC/LPV/r) /
Loading…
test image
Compass Business Partners Ltd.

UK

Loading…
COVID Moonshot /
Loading…
test image
Daiichi Sankyo

Japan

Loading…
Chagas Hit-to-lead /
Daiichi Sankyo Hit-to-lead for leishmaniasis /
Daiichi Sankyo series /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Daiichi Sankyo RD Novare Co., Ltd.

Japan

Loading…
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Datametrix AG

Switzerland

Loading…
Loading…
Filaria: river blindness /
test image
Debiopharm SA

Switzerland

Loading…
Loading…
Sleeping sickness /
test image
DeepMind

UK

Loading…
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Dow AgroSciences LLC

USA

Loading…
Loading…
Chagas disease /
Sleeping sickness /
Visceral leishmaniasis /
test image
Drugabilis

France

Loading…
Flubendazole Macrofilaricide /
Loading…
test image
E.I du Pont de Nemours

USA

Loading…
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Eisai Co., Ltd.

Japan

Loading…
Azoles E1224 /
DNDI-6174 /
Fosravuconazole /
New benznidazole regimens /
New mycetoma treatments /
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Elanco Animal Health

Germany

Loading…
Helminth Elimination Platform (HELP) /
Loading…
test image
Enamine Ltd.

Ukraine

Loading…
COVID Moonshot /
Loading…
test image
Endolytics

USA

Loading…
VL-2098 /
Loading…
test image
Epichem

Australia

Loading…
Chagas C205 series /
Chagas Hit-to-lead /
DNDI-6174 /
DNDI-8526 (S07 series) /
Fenarimol /
Leishmaniasis hit-to-lead /
Leishmaniasis L205 series /
Screening and lead optimization of new compounds for Chagas disease (>300,000 compounds) /
Two series of fenarimols for the treatment of Chagas disease /
Loading…
test image
Eurice – European Research and Project Office GmbH

Germany

Loading…
Oxfendazole /
Loading…
test image
Eurofarma

Brazil

Loading…
Leishmaniasis hit-to-lead /
Loading…
Cutaneous leishmaniasis /
Visceral leishmaniasis /
test image
Eurofins CEREP

France

Loading…
Aminopyrazoles /
Chagas C205 series /
Leishmaniasis L205 series /
Loading…
test image
Eurofins Panlabs

USA

Loading…
Aminopyrazoles /
Leishmaniasis L205 series /
Loading…
test image
Eurofins Panlabs Thailand

Thailand

Loading…
Loading…
Visceral leishmaniasis /
test image
Eurofins-Optimed

France

Loading…
Fexinidazole/Miltefosine Combination (VL) /
Loading…
test image
Evolva SA

Switzerland

Loading…
Loading…
Sleeping sickness /
Visceral leishmaniasis /
test image
Exeltis

USA

Loading…
Loading…
Chagas disease /
test image
Farmanguinhos – Fiocruz

Brazil

Loading…
ASMQ /
Ravidasvir + sofosbuvir /
Loading…
test image
FP Clinical Pharma – Ethel Feleder

Argentina

Loading…
New benznidazole regimens /
Loading…
test image
Genomics Institute of The Novartis Research Foundation (GNF)

USA

Loading…
Loading…
Visceral leishmaniasis /
test image
Genzyme (now Sanofi-Genzyme)

USA

Loading…
Loading…
Sleeping sickness /
Visceral leishmaniasis /
test image
Gilead Sciences

USA

Loading…
Loading…
Visceral leishmaniasis /
test image
GlaxoSmithKline (GSK)

UK

Loading…
CF series /
DNDI-6174 /
DNDI-6899 (GSK899/DDD853651) /
GSK245 (DDD1305143) /
UW series /
Loading…
test image
GlaxoSmithKline (GSK) – Spain

Spain

Loading…
Chagas Hit-to-lead /
DNDI-6899 (GSK899/DDD853651) /
GSK245 (DDD1305143) /
Leishmaniasis hit-to-lead /
Screening Chagas disease /
Screening Filarial disease /
Screening leishmaniasis /
UW series /
Loading…
test image
Hammersmith Medicines Research

UK

Loading…
Emodepside /
Loading…
test image
Humax Pharmaceutical

Colombia

Loading…
Anfoleish (CL) /
Loading…
test image
i+solutions

The Netherlands

Loading…
VL-0208 /
Loading…
test image
Iktos

France

Loading…
Loading…
Visceral leishmaniasis /
test image
ImaBiotech

France

Loading…
Loading…
Cutaneous leishmaniasis /
test image
InfYnity Biomarkers

France

Loading…
Biomarkers /
Loading…
Chagas disease /
test image
Instituto Nacional de Laboratorios de Salud (INLASA)

Bolivia

Loading…
Chagas Access Project /
Loading…
test image
Insud Pharma

Argentina

Loading…
Ravidasvir + sofosbuvir /
Loading…
Chagas disease /
test image
Intertek

UK

Loading…
Loading…
Visceral leishmaniasis /
test image
ITR Japan, BoZo Research Center

Japan

Loading…
DNDI-6166 (CC6166) /
Loading…
test image
Janssen Research & Development LLC

USA

Loading…
Chagas Hit-to-lead /
Flubendazole Macrofilaricide /
Loading…
Chagas disease /
test image
Johnson & Johnson

USA

Loading…
Flubendazole Macrofilaricide /
Screening Chagas disease /
Screening Filarial disease /
Screening leishmaniasis /
Loading…
Chagas disease /
test image
Laboratorio Elea Phoenix S.A.

Argentina

Loading…
Chagas Platform /
New benznidazole regimens /
Paediatric Benznidazole /
Ravidasvir + sofosbuvir /
Loading…
test image
Lafepe Laboratório Farmacêutico do Estado de Pernambuco S/A

Brazil

Loading…
Chagas Access Project /
Chagas Platform /
Paediatric Benznidazole /
redeLEISH Network /
Loading…
test image
LAT Research

Argentina

Loading…
Azoles E1224 /
Loading…
test image
Macleods Pharmaceuticals Ltd

India

Loading…
Loading…
Visceral leishmaniasis /
test image
Margan Clinical Research Organization

Ghana

Loading…
Loading…
Filaria: river blindness /
test image
MC Toxicology Consulting GmbH

Austria

Loading…
Loading…
Filaria: river blindness /
test image
MedChemica Ltd.

UK

Loading…
ASAP-0017445 (Moonshot ASAP) /
AViDD ASAP /
COVID Moonshot /
Loading…
test image
Merck

USA

Loading…
Chagas Hit-to-lead /
Leishmaniasis hit-to-lead /
Screening Chagas disease /
Screening Filarial disease /
Screening leishmaniasis /
Loading…
test image
Merck KGaA

Germany

Loading…
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Mitsubishi Tanabe Pharma Corporation Group

Japan

Loading…
Chagas Hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Series-5824 (MT) /
Loading…
test image
Mologic Ltd.

UK

Loading…
Loading…
Visceral leishmaniasis /
test image
Mylan Laboratories Limited (a Viatris company)

India

Loading…
5FC HIV-Crypto /
Loading…
test image
Novartis

Switzerland and USA

Loading…
LXE408 Novartis for CL /
LXE408 Novartis for VL /
Loading…
Chagas disease /
Sleeping sickness /
Visceral leishmaniasis /
test image
Novartis Centre de la Recherche Santé Animale

Switzerland

Loading…
Screening Filarial disease /
Loading…
test image
Novartis Institutes for BioMedical Research

USA

Loading…
Biomarkers /
Loading…
Visceral leishmaniasis /
test image
Otsuka Pharmaceutical Co., Ltd.

Japan

Loading…
Loading…
Sleeping sickness /
Visceral leishmaniasis /
test image
Pentlands Management Systems Ltd.

UK

Loading…
Loading…
Visceral leishmaniasis /
test image
Pfizer Inc. (formerly Anacor Pharmaceuticals)

USA

Loading…
Acoziborole /
Aminopyrazoles /
DNDI-5421 & DNDI-5610 /
DNDI-6148 /
DNDI-6148 Chagas disease /
Leishmaniasis hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Successful screening collaboration leads to a new lead optimization project /
Loading…
test image
Pharco Pharmaceuticals, Inc

Egypt

Loading…
Ravidasvir + sofosbuvir /
Loading…
test image
Pharmadyn Inc.

USA

Loading…
Loading…
Sleeping sickness /
Visceral leishmaniasis /
test image
Pharmaniaga Berhad

Malaysia

Loading…
Ravidasvir + sofosbuvir /
Loading…
test image
Pharmetheus AB

Sweden

Loading…
DNDI-0690 /
VL-INNO /
Loading…
test image
Phi Pharma SA

Switzerland

Loading…
Loading…
Visceral leishmaniasis /
test image
PhinC Development

France

Loading…
Fexinidazole/Miltefosine Combination (VL) /
Loading…
test image
Phytobios

Brazil

Loading…
Screening Chagas disease /
Loading…
test image
Pierre Fabre Laboratories

France

Loading…
Screening Chagas disease /
Loading…
Chagas disease /
Visceral leishmaniasis /
test image
Polytherics (now Abzena)

UK

Loading…
Loading…
Visceral leishmaniasis /
test image
PostEra

UK/USA

Loading…
ASAP-0017445 (Moonshot ASAP) /
AViDD ASAP /
COVID Moonshot /
Loading…
test image
Presidio Pharmaceuticals, Inc

USA

Loading…
Ravidasvir + sofosbuvir /
Loading…
test image
Roche

Switzerland

Loading…
Loading…
Sleeping sickness /
test image
Roowin

France

Loading…
Loading…
Sleeping sickness /
test image
Sandexis

UK

Loading…
Aminopyrazoles /
Celgene Global Health visceral leishmaniasis series 1 /
Chagas Hit-to-lead /
DNDI-5421 & DNDI-5610 /
Leishmaniasis hit-to-lead /
Oxachagas /
Screening Chagas disease /
Loading…
test image
Sanofi

France

Loading…
Acoziborole /
ASAQ /
Chagas Hit-to-lead /
Fexinidazole for T.b. gambiense /
Leishmaniasis hit-to-lead /
Nifurtimox-eflornithine combination therapy (NECT) /
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Sanofi Merial (now Boehringer Ingelheim Animal Health Business Unit)

USA

Loading…
Screening Filarial disease /
Screening leishmaniasis /
Loading…
test image
Sanofi-Chinoin

Hungary

Loading…
Fexinidazole/Miltefosine Combination (VL) /
Loading…
test image
SAS Institute Inc. – Data for Good

USA

Loading…
Loading…
test image
SCYNEXIS Inc

USA

Loading…
DNDI-5421 & DNDI-5610 /
SCYNEXIS Inc. as part of the DNDi HAT Lead Optimization Consortium /
SCYX-1330682 & SCYX-1608210 oxaboroles /
SCYX-2035811 /
Loading…
test image
Sequella Inc.

USA

Loading…
Screening Chagas disease /
Loading…
test image
SGS, France

France

Loading…
Fexinidazole/Miltefosine Combination (VL) /
Loading…
test image
Shionogi & Co., Ltd.

Japan

Loading…
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Loading…
test image
Spotlab

Spain

Loading…
VL-INNO /
Loading…
test image
ST Pharm, Co., Ltd.

Republic of Korea

Loading…
DNDI-6148 /
DNDI-6148 Chagas disease /
Loading…
test image
Syneos Health, Llc.

USA

Loading…
Loading…
Chagas disease /
test image
Takeda Pharmaceutical Company Limited

Japan

Loading…
Aminopyrazoles /
Chagas Hit-to-lead /
DNDI-5561 /
DNDI-8526 (S07 series) /
Leishmaniasis hit-to-lead /
NTD Drug Discovery Booster Hit-to-lead /
Screening Chagas disease /
Screening leishmaniasis /
Successful screening collaboration leads to a new lead optimization project /
Loading…
test image
Thames Pharma Partners LCC

USA

Loading…
COVID Moonshot /
Loading…
test image
Thermosurgery Technologies Inc.

USA

Loading…
Miltefosine + thermotherapy for cutaneous leishmaniasis /
Loading…
test image
Trade Factors Overseas Ltd.

UK

Loading…
Loading…
Sleeping sickness /
test image
Venn Life Sciences

Ireland

Loading…
Loading…
Chagas disease /
Sleeping sickness /
test image
WuXi AppTech

China

Loading…
Aminopyrazoles /
Celgene Global Health visceral leishmaniasis series 1 /
Chagas C205 series /
DNDI-5421 & DNDI-5610 /
Leishmaniasis L205 series /
Nitroimidazole (Chagas) /
Oxachagas /
SCYX-2035811 /
Loading…
test image
Zenufa

Tanzania

Loading…
ASAQ /
Loading…
test image
Zhejiang Ausun Pharmaceutical Co., Ltd.

China

Loading…
Loading…
Hepatitis C /
test image
Zoetis (formerly Pfizer Animal Health)

USA

Loading…
Screening Chagas disease /
Screening leishmaniasis /
Loading…
test image
Zydus Cadila Healthcare Ltd.

India

Loading…
Loading…
Visceral leishmaniasis /
test image

Become a partner

Help us bring the best science to the most neglected.

contact us
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License